Patent Expirations — Q4 2026
Loss of exclusivity (LOE) marks when a drug's patent and regulatory exclusivity protections lapse, allowing generic or biosimilar competitors to enter the market. For companies with marketed products, the patent cliff can sharply erode revenue, while for competitors it opens a new commercial opportunity. Dates are sourced from the FDA Orange Book.
0 patent expirations in Q4 2026. Updated .
No patent expirations tracked for Q4 2026. See all patent expirations →